Study for Cognitive and Genetic Characterization of a 45-65 Years Old Population

Sponsor

Barcelonabeta Brain Research Center, Pasqual Maragall Foundation (Other)

Overall Status

Completed

CT.gov ID

NCT01835717

Collaborator

Obra Social La Caixa, Spain (Other)

2,743

Enrollment

Location

Actual Duration (Months)

29.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Before Alzheimer's disease (AD) clinical symptoms appear, there is a long period when changes in the brain occur. In this long asymptomatic period or preclinical phase, studies with populations at risk of developing AD have shown cognitive differences compared to control groups without such risk. There is a need for short, sensitive, easily administered, reproducible, non-expensive and independent of socio-demographic influences tests enabling the detection of pre-symptomatic variations in memory, when the memory decline is still within a normal range.

Study main hypothesis: When evaluated with high-demanding tests of memory and executive function, the cognitive performance of cognitive healthy people aged between 45 and 65 and, extensively, to a group of up to 75 years, will vary significantly depending on clinical, socio-demographic and genetic features

Condition or Disease	Intervention/Treatment	Phase
Healthy Individuals

Detailed Description

The purpose of Study 45-65 is to assess if:

Endogenous factors (clinical history, risk factors, genetic factors APOE4, etc…), exogenous (socio-demographic, ambient and lifestyle variables) and cognitive reserve (including bilingualism) influence cognitive performance.
New and/or updated tests translated and validated in Spanish and Catalan when needed, will provide accurate and sensitive measurements of the variability of cognitive performance in this target population, representative of the preclinical phase of Alzheimer's disease.

An optional visit is offered to study participants that includes: cerebral magnetic resonance, vascular ultrasound and olfactory testing.

Study Design

Study Type:

Observational

Actual Enrollment :

2743 participants

Observational Model:

Cohort

Time Perspective:

Cross-Sectional

Official Title:

Cross-sectional Study for Cognitive and Genetic Characterization of a 45-65 Years Old Population

Actual Study Start Date :

Apr 1, 2013

Actual Primary Completion Date :

Aug 30, 2019

Actual Study Completion Date :

Dec 31, 2020

Arms and Interventions

Arm	Intervention/Treatment
Cognitively normal individuals

Outcome Measures

Primary Outcome Measures

Factors influencing the cognitive performance through demanding tests of episodic memory and executive function [single Visit (up to 3 hours)]
The following tests will be administered: Verbal episodic memory: MBT (Memory Binding Test) WAIS-IV subsets: 1 Perceptual reasoning (Visual Puzzles) 2 Logical reasoning (Matrix Reasoning) 3 Executive attention and working memory (Digit span) 4 Speed of processing (Coding) 5 Abstract verbal reasoning (Similarities) Factors to be considered: Hypertension, diabetes mellitus, and metabolic syndrome APOE4 Cognitive reserve (including bilingualism) Pollution, exposure to toxics, diet
Culturally adapted validation in Spanish and Catalan of the MBT and determination of normative data for the population under study. [single visit (up to 3 hours)]

Secondary Outcome Measures

Assessment of the equivalence of the in person and over the phone administration to the close relative of the Clinical Dementia Rating (CDR). [single visit/telephone conversation (up to 10 min)]
Genetic features of the population [8 months after study start]
APOE genotyping is being performed
Identification of genetic determinants of neuroimaging phenotypes associated to Alzheimer's disease. [5 years and 8 months after study start]
Brain MR (magnetic resonance) as well as GWAS (genome-wide association studies) are being performed
Assessment of the relationship between olfactory and cognitive performance [5 years and 8 months after study start]
Olfaction is assessed with the Burghart Medical Technology (Wedel, Germany) kit containing 16 sniffing sticks
Analysis of the relationship between subclinical atherosclerosis and brain changes, cognitive performance and APOE genotype [6 years and 8 months after study start]
Vascular ultrasound of femoral and carotid arteries will be performed

Eligibility Criteria

Criteria

Ages Eligible for Study:

45 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Men and women, aged between 45 and 75 years
Spanish and/or Catalan speakers
Agreement with the study procedures and tests:
Clinical Interview and questionnaires associated to risk factors
Cognitive tests
Blood sample extraction for DNA analysis
Close relative involvement for functional evaluation of the volunteer
Signature of informed consent

Exclusion Criteria:

Cognitive impairment: MMSE <26, o MIS <6, or orientation subtest of the Barcelona Test II <68, o category fluency (animals) <12
Functional status impairment: CDR > 0
Severe auditory and/or visual impairment
Neurodevelopmental and/or psychomotor disorder
Significant diseases that could currently interfere with cognition: renal failure on hemodialysis, liver cirrhosis, chronic lung disease with oxygen therapy, solid organ transplantation, fibromyalgia, active cancer in treatment or any other disease the investigator considers could affect the participant cognition
Major psychiatric disorders (DSM-IV-TR) or diseases that could affect cognitive abilities: major depression, bipolar disorder, schizophrenia and dementia.
Neurological disorders: Parkinson's disease, stroke, epilepsy and treatment with frequent seizures (> 1/month) in the past year, multiple sclerosis or other serious neurological disease.
Brain injury interfering with cognition: history of head trauma with parenchymal lesion or extraaxial macroscopic large vessel ischemic stroke or hemorrhagic stroke, brain surgery, brain tumors and other causes that can generate acquired brain damage (cerebral chemotherapy or radiotherapy)
Family history of Alzheimer's disease with autosomal dominant (3 affected in two different generations) and early onset age (<60 years).